⌕
Telix Pharmaceuticals · TLX · Nasdaq
Tenet 41 · Weak
Compare
$8.86−0.73%At closeTenet 41 · Weak
$8.86−0.07 (−0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Telix Pharmaceuticals (TLX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 11, 2026 · 02:00 ET
Telix to Participate in UBS Global Biopharma Conference

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will participate in the upcoming UBS Global Biopharma Conference in London (UK)…

● MarketBeatNov 4, 2026 · 03:14 ET
Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chai…

● Seeking AlphaOct 23, 2026 · 04:13 ET
Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precis…

● GlobeNewsWireOct 20, 2026 · 18:10 ETCOMPANY'S OWN WORDS
Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the qu…

● GlobeNewsWireOct 19, 2026 · 01:30 ET
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.…

● GlobeNewsWireOct 19, 2026 · 01:30 ETCOMPANY'S OWN WORDS
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion…

● GlobeNewsWireOct 9, 2026 · 07:45 ET
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with incre…

● GlobeNewsWireOct 6, 2026 · 06:30 ET
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed …

● GlobeNewsWireOct 1, 2026 · 01:00 ET
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®

IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics…

● Zacks Investment ResearchSep 30, 2026 · 10:56 ET
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the posit…

● Defense WorldSep 30, 2026 · 06:21 ET
Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ: TLX - Get Free Report) saw unusually-strong trading volume on Monday. Approximately 231,111 shares changed hands during trading, an increase of 4% from the previous session's volume…

● Seeking AlphaSep 22, 2026 · 18:29 ET
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript

Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript…

● Seeking AlphaSep 22, 2026 · 06:16 ET
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript

Telix Pharmaceuticals Limited (TLX) M&A Call Transcript…

● GlobeNewsWireSep 20, 2026 · 20:55 ETCOMPANY'S OWN WORDS
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger wit…

● ReutersSep 20, 2026 · 19:01 ET
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion

Australia's Telix Pharmaceuticals ​said on ‌Monday it has ​agreed to ​acquire Germany-based ITM ⁠Isotope ​Technologies Munich SE ​for about $1.65 billion on a ​cash- ​and debt-free basis.…

● Seeking AlphaSep 16, 2026 · 16:10 ET
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement

Telix Pharmaceuticals is maintained at a “Buy” rating, supported by FDA approval of PIXCLARA and robust pipeline progress in oncology diagnostics and therapeutics. The company achieved the first FDA-approved FET-PET imag…

● Seeking AlphaSep 14, 2026 · 12:51 ET
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● BenzingaSep 14, 2026 · 09:50 ET
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug

On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagno…

● GlobeNewsWireSep 14, 2026 · 06:30 ET
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) ha…

● GlobeNewsWireSep 9, 2026 · 06:30 ETCOMPANY'S OWN WORDS
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin R…

● GlobeNewsWireSep 1, 2026 · 18:18 ET
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of it…

● GlobeNewsWireAug 31, 2026 · 18:21 ET
Telix Appoints David Gill as Chair

MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Bo…

● Seeking AlphaAug 24, 2026 · 18:25 ET
Telix Pharmaceuticals: Execution Is The Name Of The Game Here

Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain …

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just TLX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.